Strata Critical Medical Earnings Call Transcripts
Fiscal Year 2026
-
The company leverages an asset-light, end-to-end logistics and clinical platform to drive growth in the fragmented organ transplant market, benefiting from regulatory changes and advances in perfusion technology. Its agnostic approach to devices, national footprint, and targeted acquisitions position it for continued above-market expansion.
Fiscal Year 2025
-
Q4 2025 saw 35% organic growth, record revenue, and margin expansion, driven by logistics and clinical integration. 2026 guidance was raised on strong volumes and new customer wins, with continued M&A and asset-light strategy supporting growth.
-
Strata has transformed into a pure-play, end-to-end provider for organ transplant and cardiac care, leveraging an open-source, asset-light model with selective aircraft ownership and proprietary tech. Financial guidance targets organic EBITDA doubling by 2029, with significant upside from M&A, cross-selling, and regulatory tailwinds.
-
Revenue grew 36.7% year-over-year to $49.3M in Q3 2025, with record segment-adjusted EBITDA and margin improvement. Raised 2025 revenue guidance to $185M–$195M, reaffirmed EBITDA outlook, and ended the quarter with no debt and $76M in cash.
-
Divesting the passenger business enables a focused push into the fast-growing medical logistics market, leveraging regulatory and technological shifts to expand services and improve margins. Strategic partnerships and an asset-light model drive competitive advantage and financial efficiency.
-
A major divestiture will refocus the business on medical logistics, leveraging a large, flexible aircraft network and expanding high-margin ancillary services. Regulatory and technological advances are driving market growth, with strong financial performance and high customer retention expected to continue.
-
Announced sale of the passenger business for up to $125M, transforming into a pure-play medical air mobility provider with strong Q2 medical revenue growth of 17.6% year-over-year. Medical segment now drives 60% of revenue and is positioned for further organic and M&A-driven expansion.
-
The business has achieved profitability ahead of schedule, with strong growth in both passenger and medical transport, especially in organ logistics. EVTOL integration is expected to drive exponential growth, supported by a robust brand, innovative partnerships, and a flexible asset-light model.
-
The company is leading the shift from helicopters to EVTOLs with an asset-light model and strong infrastructure. Its medical transport business now surpasses passenger services in size and profitability, with double-digit growth. Profitability came a year early, and further growth is expected via acquisitions and expanding EVTOL use.
-
The conference highlighted strong growth and margin expansion in both medical and passenger segments, with technology and infrastructure positioning the business for the upcoming eVTOL transition around 2026. Capital allocation remains focused on medical and logistics, with significant upside in both segments.
-
Q1 saw 11% revenue growth (ex-Canada), record Passenger segment profitability, and flat medical revenue with margin pressure from maintenance downtime. Guidance for double-digit medical growth and improved margins in H2 2025 was reiterated, with $120M cash and no debt.
-
Profitability was achieved in both medical and passenger segments, with medical now the main revenue driver and strong growth expected from regulatory changes, technology, and expanded services. The company is well-positioned for the eVTOL transition, leveraging its infrastructure, brand, and operational efficiencies.
-
The conference highlighted strong growth in medical organ transport, driven by regulatory and technological advances, and a profitable, asset-light passenger business focused on exclusive infrastructure and partnerships. Strategic investments and M&A support expansion, with full-year profitability expected in 2024.
Fiscal Year 2024
-
Achieved first full year of Adjusted EBITDA profitability with strong revenue and margin growth in both medical and passenger segments. 2025 guidance anticipates continued revenue growth, margin expansion, and strategic investments, despite near-term volatility in medical volumes and maintenance costs.
-
The company has transformed into a leading urban air mobility and medical transport provider, achieving early profitability in its passenger segment and rapid growth in medical logistics. With 20% market share in organ transport and strong hospital partnerships, it is poised for further expansion, especially as eVTOL technology and new logistics verticals emerge.
-
Achieved record profitability in both passenger and medical segments, with Adjusted EBITDA up fivefold year-over-year and strong cash flow. Exited unprofitable markets, restructured Europe, and formed a strategic alliance with OrganOx, while reiterating 2024 guidance and maintaining a strong balance sheet.
-
Q2 2024 saw record revenue, first positive Adjusted EBITDA, and strong growth in both medical and passenger segments. Medical margins and returns on owned assets expanded, while the company exited unprofitable Canadian operations and executed share repurchases. Guidance for 2024 and 2025 was reiterated.